Mitochondria-Targeted Peptide Accelerates ATP Recovery and Reduces Ischemic Kidney Injury
Hazel H. Szeto,Shaoyi Liu,Yi Soong,Dunli Wu,Shaun Darrah,Feng Ying Cheng,Zhihong Zhao,Michael Ganger,Clara Y. Tow,Surya V. Seshan +9 more
TLDR
Treatment with SS-31 protected mitochondrial structure and respiration during early reperfusion, accelerated recovery of ATP, reduced apoptosis and necrosis of tubular cells, and abrogated tubular dysfunction, suggesting that it may protect against ischemic renal injury.Abstract:
The burst of reactive oxygen species (ROS) during reperfusion of ischemic tissues can trigger the opening of the mitochondrial permeability transition (MPT) pore, resulting in mitochondrial depolarization, decreased ATP synthesis, and increased ROS production. Rapid recovery of ATP upon reperfusion is essential for survival of tubular cells, and inhibition of oxidative damage can limit inflammation. SS-31 is a mitochondria-targeted tetrapeptide that can scavenge mitochondrial ROS and inhibit MPT, suggesting that it may protect against ischemic renal injury. Here, in a rat model of ischemia-reperfusion (IR) injury, treatment with SS-31 protected mitochondrial structure and respiration during early reperfusion, accelerated recovery of ATP, reduced apoptosis and necrosis of tubular cells, and abrogated tubular dysfunction. In addition, SS-31 reduced medullary vascular congestion, decreased IR-mediated oxidative stress and the inflammatory response, and accelerated the proliferation of surviving tubular cells as early as 1 day after reperfusion. In summary, these results support MPT as an upstream target for pharmacologic intervention in IR injury and support early protection of mitochondrial function as a therapeutic maneuver to prevent tubular apoptosis and necrosis, reduce oxidative stress, and reduce inflammation. SS-31 holds promise for the prevention and treatment of acute kidney injury.read more
Citations
More filters
Journal ArticleDOI
Acute Kidney Injury.
TL;DR: This work reviews recent findings relating to the renal vasculature and cellular stress responses and identifies macrophages, growth-arrested tubular epithelial cells, the endothelium, and surrounding pericytes are key players in the progression to chronic disease.
Journal ArticleDOI
Expert consensus document: Mitochondrial function as a therapeutic target in heart failure
David Brown,Justin B. Perry,Mitchell E. Allen,Hani N. Sabbah,Hani N. Sabbah,Brian L. Stauffer,Saame Raza Shaikh,John G.F. Cleland,Wilson S. Colucci,Javed Butler,Adriaan A. Voors,Stefan D. Anker,Bertram Pitt,Bertram Pitt,Burkert Pieske,Gerasimos Filippatos,Stephen J. Greene,Mihai Gheorghiade +17 more
TL;DR: In this article, insights into the mechanisms of mitochondrial dysfunction in heart failure are presented, along with an overview of emerging treatments with the potential to improve the function of the failing heart by targeting mitochondria.
Journal ArticleDOI
Renal tubule injury: a driving force toward chronic kidney disease.
TL;DR: A better understanding of the mechanisms by which tubular injury drives inflammation and fibrosis is necessary for the development of therapeutics to halt the progression of chronic kidney disease.
Journal ArticleDOI
Renal ischemia/reperfusion injury; from pathophysiology to treatment.
Maryam Malek,Mehdi Nematbakhsh +1 more
TL;DR: This review summarizes some important potential mechanisms and therapeutic approaches in renal IRI and discusses the design of more targeted therapies to prevent and treatment the injury.
Journal ArticleDOI
First‐in‐class cardiolipin‐protective compound as a therapeutic agent to restore mitochondrial bioenergetics
TL;DR: SS‐31 represents a new class of compounds that can recharge the cellular powerhouse and restore bioenergetics and provides an update of its clinical development programme.
References
More filters
Journal ArticleDOI
Inhibition of Mitochondrial Membrane Permeability as a Putative Pharmacological Target for Cardioprotection
TL;DR: Drugs able to block or to limit mitochondrial membrane permeabilization may be cytoprotective during ischemia-reperfusion, because mitochondria have become the subject of growing interest in myocardial ischemian injury since they are strongly involved in the regulation of the apoptotic process.
Journal ArticleDOI
Cyclosporine protects against ischemia/reperfusion injury in rat kidneys.
TL;DR: From the results of the study, it can be concluded that low-dose CsA pretreatment preconditions the rat kidneys against subsequent ischemia/reperfusion injury.
Journal ArticleDOI
Expression and molecular regulation of Na(+)-K(+)-ATPase after renal ischemia
TL;DR: The results suggest that recycling of misplaced units rather than new Na(+)-K(+-ATPase production is the means by which renal epithelia initially repolarize after ischemic injury.
Journal ArticleDOI
Cyclosporin and Organ Specific Toxicity: Clinical Aspects, Pharmacogenetics and Perspectives
Alberto Magnasco,Andrea Rossi,Paolo Catarsi,Rosanna Gusmano,Fabrizio Ginevri,Francesco Perfumo,Gian Marco Ghiggeri +6 more
TL;DR: Overall, available studies suggest a good degree of safety related to appropriate drug dosages even if they require an adequate degree of surveillance in case of rapid changes of renal functions and long term evaluation of renal pathology.
Journal ArticleDOI
Red cell trapping after ischemia and long-term kidney damage. Influence of hematocrit
TL;DR: The results showed that an increase in the duration of ischemia increased the RBC trapping, as measured by 51Cr-labeled erythrocytes, in a dose-dependent manner, and it was suggested that cortical atrophy is secondary to the medullary injury, and is brought about to avoid extensive water and salt losses.